Phase 1 open-label, multicenter, dose escalation study of mRNA-2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma.
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2017
At a glance
- Drugs MRNA-2416 (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions
- 21 Sep 2017 New trial record